Nurix (NRIX) Reiterated at Buy at Needham & Company, "Expect Value Creation in 2022 Across Nurix Pipeline"
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $48.00 price target on Nurix (NASDAQ: NRIX) in light ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
